FDA 483 - Zhejiang Langhua Pharmaceutical Co. Ltd. - August 30, 2024

An FDA inspection of Zhejiang Langhua Pharmaceutical Co. Ltd., an API drug manufacturer, revealed significant deficiencies in laboratory controls and master batch production records. The firm failed to implement scientifically sound water sampling methods and lacked established time limits and detailed production instructions in their batch records, indicating potential quality control issues.